Loading
HKSEHealthcareMedical - Devices
Latest quote
HK$4.945
+HK$0.175 · +3.67%
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
Latest quote
HK$4.945
+HK$0.175 · +3.67%
Regular session · HKT · Market data may be delayed.
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
Day range
Current HK$4.945
52-week range
Current HK$4.945
Regular session · HKT · Market data may be delayed.
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
Day range
Current HK$4.945
52-week range
Current HK$4.945
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 712.87M CNY | 615.48M CNY | 441.13M CNY | 250.83M CNY | 136.53M CNY |
| Cost of goods sold | 226.82M CNY | 181.86M CNY | 115.76M CNY | 74.63M CNY | 40.88M CNY |
| Gross profit | 486.05M CNY | 433.62M CNY | 325.37M CNY | 176.2M CNY | 95.65M CNY |
| Research and development | 266.72M CNY | 233.13M CNY | 293.42M CNY | 373.13M CNY | 454.42M CNY |
| Selling, general, and administrative | 446.83M CNY | 479.44M CNY | 466.62M CNY | 365.06M CNY | 207.68M CNY |
| Operating expenses | 684.72M CNY | 672.97M CNY | 756.13M CNY | 618.75M CNY | 694.46M CNY |
| Interest income | 7.81M CNY | 22.48M CNY | 39.44M CNY | 46.63M CNY | 24.77M CNY |
| Interest expense | 11.73M CNY | 4.74M CNY | 178K CNY | 2.32M CNY | 186K CNY |
| Depreciation and amortization | 62.29M CNY | 53.41M CNY | 42.8M CNY | 36.01M CNY | 27.49M CNY |
| Operating income | −198.67M CNY | −239.35M CNY | −430.76M CNY | −442.55M CNY | −598.8M CNY |
| Net income | −203.29M CNY | −226.58M CNY | −392.53M CNY | −407.81M CNY | −574.22M CNY |
Company facts updated Sep 14, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Dimensional - Emerging Markets Core Equity 2 ETFDFEM199.95K0.00%9.62B USD0.39%$40.53+1.12%
Dimensional World ex U.S. Core Equity 2 ETFDFAX133.5K0.00%12.61B USD0.28%$38.06+0.95%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX125.58K0.02%684.6M USD0.65%$72.61+0.30%
Dimensional - Emerging Core Equity Market ETFDFAE118.26K0.00%10.17B USD0.29%$40.13+1.24%
State Street SPDR Portfolio Emerging Markets ETFSPEM90.75K0.00%17.86B USD0.07%$52.51+0.67%
Dimensional Emerging Markets Sustainability Core 1 ETFDFSE28.04K0.00%648.91M USD0.44%$49.21+1.46%
iShares Neuroscience and Healthcare ETFIBRN22.56K0.30%7.48M USD0.47%$37.4262+0.27%Dimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional World ex U.S. Core Equity 2 ETFDFAXState Street SPDR S&P Emerging Markets Small Cap ETFEWXDimensional - Emerging Core Equity Market ETFDFAEState Street SPDR Portfolio Emerging Markets ETFSPEMDimensional Emerging Markets Sustainability Core 1 ETFDFSEiShares Neuroscience and Healthcare ETFIBRNAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
